SEC Filings

DEFR14A
MEDTRONIC PLC filed this Form DEFR14A on 10/11/2017
Entire Document
 

MEDTRONIC PLC WORLD WIDE REVENUE: GEOGRAPHIC(1) (Unaudited)

 

 FISCAL YEAR AS REPORTED  FISCAL YEAR CONSTANT CURRENCY ADJUSTED
(in millions)     FY17
Total
   FY16
Total
   Reported
Growth(4)
   Currency
Impact on
Revenue
   FY17
Total
   Constant
Currency
Growth(3)(4)
U.S.  $5,454   $5,369    2%  $   $5,454    2%
Non-U.S. Developed   3,393    3,283    3    (3)   3,396    3 
Emerging Markets   1,651    1,566    5    (34)   1,685    8 
Cardiac & Vascular Group(2)   10,498    10,218    3    (37)   10,535    3 
U.S.   5,049    5,014    1        5,049    1 
Non-U.S. Developed   3,479    3,299    5    45    3,434    4 
Emerging Markets   1,391    1,250    11    (28)   1,419    14 
Minimally Invasive Therapies Group   9,919    9,563    4    17    9,902    4 
U.S.   5,012    4,899    2        5,012    2 
Non-U.S. Developed   1,588    1,542    3    14    1,574    2 
Emerging Markets   766    747    3    (15)   781    5 
Restorative Therapies Group(2)   7,366    7,188    2    (1)   7,367    2 
U.S.   1,148    1,140    1        1,148    1 
Non-U.S. Developed   625    584    7    (12)   637    9 
Emerging Markets   154    140    10    (1)   155    11 
Diabetes Group   1,927    1,864    3    (13)   1,940    4 
U.S.   16,663    16,422    1        16,663    1 
Non-U.S. Developed   9,085    8,708    4    44    9,041    4 
Emerging Markets   3,962    3,703    7    (78)   4,040    9 
TOTAL  $29,710   $28,833    3%  $(34)  $29,744    3%

 

(1) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.
(2) In fiscal year 2017, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from certain product lines in Restorative Therapies Group to Cardiac & Vascular Group’s Aortic & Peripheral Vascular division. As a result, fiscal year 2016 results have been recast to adjust for this realignment.
(3) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between current and prior year periods using average exchange rates in effect during the applicable prior year period.
(4) Fiscal year 2016 was a 53-week year, with the extra week included in the first quarter results. While it is difficult to calculate the impact of the extra week, the Company estimates that the extra week impact on worldwide, fiscal year 2016 first quarter revenue was approximately $450 million. Excluding the approximately $450 million from fiscal year 2016 total revenue would result in approximately 5 percent growth on a constant currency, constant week basis.

 

MEDTRONIC PLC   2017 Proxy Statement    A-3

 
X